Chronic Lymphocytic Leukemia News
Most patients with previously untreated CLL experienced a persistent MRD benefit with a fixed-dose, obinutuzumab-ibrutinib–based treatment approach.
Sometimes the distinctions between cancer treatment groups are a little blurry. Here’s a guide to their definitions and origins.
A recent HHS announcement spurred concern that FDA oversight of LDTs was eroding, threatening patient safety — but the reality is less dire.
Fixed-duration venetoclax plus rituximab provides sustained, durable response for patients with relapsed chronic lymphocytic leukemia.
Venetoclax plus obinutuzumab appears to yield good responses for a limited duration among patients with previously untreated CLL.
Risks of moving clinical trials online include missing key information about the patient experience — and higher dropout rates could also impair the overall quality of trials.
Most patients achieved deep remission after a 14-month regimen of obinutuzumab, ibrutinib, and venetoclax.
Patients with chronic lymphocytic leukemia/small lymphocytic lymphoma who had an L265P MYD88 mutation were uncommon and had distinct features.
Risk-adapted dosing of bendamustine and rituximab may be beneficial and tolerable for elderly patients with CLL, a retrospective study found.
Researchers reviewed promising advances in therapy options for patients with CLL and the challenges associated with these new treatments.
Prior treatment with at least 1 novel agent did not affect allogeneic transplant outcomes among patients with CLL.
Sustained remission of CLL is associated with enrichment of a less-differentiated, early-memory phenotype of T cells in the apheresis product used to make CAR-T therapies.
Infections often precede a formal diagnosis of CLL. Researchers found that antimicrobial use began to rise 6 years prior to CLL diagnosis.
In this study, a cohort of patients with newly diagnosed CLL was followed to identify the incidence of SCC skin cancer and its associated risk factors in this population.
These study findings show the risk and incidence of serious bacterial infection and its effect on mortality for patients with CLL.
The social media platform can be useful as an education tool for oncologists to stay up to date on new research in oncology — but physicians still need to be mindful of the information sources.
It remains important to interrogate how structural discrimination influences the collection of patient-reported outcomes.
Ibrutinib-mediated macrophage inhibition may underlie an increased risk of invasive fungal infection in patients with CLL treated with this agent.
Obinutuzumab plus venetoclax was associated with improved outcomes compared with obinutuzumab plus chlorambucil, regardless of the presence of unfavorable genetic prognostic factors.
Black patients were half as likely to receive remdesivir as White patients, according to researchers from the CCC19.